Solkane®134a pharma and Solkane®227 pharma
Final Qualification of Cirrus Pharmaceutical, Inc. for batch release testing of Solkane® propellants
As of August 2008 Cirrus Inc is qualified to act as a designated independent lab as required by the FDA to perform acceptance testing for Solvay’s Solkane® propellants on to the methods provided by Solvay Fluor. Cirrus Inc. performed acceptance testing for Solvay’s propellants Solkane® 134a pharma and Solkane® 227 pharma and met all acceptance criteria.
This service enables customers to further improve their product development, speed up their registration process and even can be used for HFA propellant supplier qualification to satisfy the growing market needs of HFA propellants during CFC phase out in MDIs.
Cirrus Pharmaceuticals is a contract product development company located in North Carolina, USA that assists biotechnology and pharmaceutical companies with formulation development and regulated testing of pharmaceutical products throughout their development.
The contact people are Peter Jannick of Solvay Fluor Germany, Don Magid of Solvay Chemicals US and Jean-Marc Bovet of Cirrus Pharmaceuticals, Inc.
|
